Capsule Summary Slidesets

Share

Program Content

Activities

  • VALENTINE-PTCL01
    VALENTINE-PTCL01: Primary Results of Phase II Trial of Valemetostat Tosylate in Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2023

  • TRANSCEND CLL 004 Update
    TRANSCEND CLL 004: 24-Mo Follow-up of Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • EPCORE NHL 5
    EPCORE NHL-5: Results From Arm 1 of a Phase Ib/II Trial Evaluating SC Epcoritamab + Lenalidomide in Relapsed/Refractory DLBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • ELARA 3-Year Follow-up
    Phase II ELARA: 3-Year Follow-up of Tisagenlecleucel in R/R Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • ELEVATE TN: 6 Yr Update
    ELEVATE-TN 6-Yr Update: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • TRANSCEND FL at ASH 2023
    TRANSCEND FL: Lisocabtagene Maraleucel as Second-Line Therapy for Patients With High-Risk R/R Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • ELM-2 Exploratory ctDNA Analysis
    ELM-2 Exploratory Analysis: Association Between ctDNA-Assessed Measurable Residual Disease Status and PFS With Odronextamab in R/R FL and DLBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • 1L Mosunetuzumab SC for FL
    Mosunetuzumab SC as First-line Therapy for Patients With High Tumor Burden Follicular Lymphoma: Results of a Phase II Study
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • AN + AD in Early cHL
    Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine in Early-Stage Classical Hodgkin Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • ELM-2 Final Analysis
    ELM-2: Final Analysis From Phase II Trial of Odronextamab in Relapsed/Refractory DLBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • SWOG S1826
    SWOG S1826: Nivolumab-AVD vs BV-AVD in Older Patients (Aged ≥60 Years) With Advanced Stage Classic Hodgkin Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • SYMPATICO
    SYMPATICO: Phase III Trial of Ibrutinib + Venetoclax vs Ibrutinib + Placebo for Patients With R/R Mantle Cell Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • BOVen in 1L TP53mut MCL
    BOVen: Phase II Trial of Zanubrutinib, Obinutuzmab, and Venetoclax in Treatment-Naive TP53-Mutated Mantle Cell Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.